KEVIN VARGHESE: Open Payments
NPI 1477181071 · KANKAKEE, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$758 in 34 payments from 12 companies in 2025. Trend: 2023 $293 · 2024 $169 · 2025 $758
Food & beverage: $758
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $219 |
| Alkermes, Inc. | 5 | $89 |
| Tris Pharma Inc | 4 | $81 |
| Vanda Pharmaceuticals Inc. | 2 | $71 |
| Teva Pharmaceuticals USA, Inc. | 3 | $68 |
| Lundbeck LLC | 4 | $62 |
| Neurocrine BioSciences, Inc. | 2 | $49 |
| Luye Pharma (USA) Ltd. | 2 | $45 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, Dyanavel XR, FANAPT, UZEDY, INGREZZA, ERZOFRI EXTENDED-RELEASE.
Industry payments across IL — which companies pay providers there.
